Maraviroc Switch Collaborative Study

Inclusion Criteria: * Documented HIV-1 infection by a licensed diagnostic test at any time prior to study entry * Age \>18 years * HIV-1 RNA \<200 copies/mL plasma for at least 24 weeks * Stable (\>24 weeks) ART including two N(t)RTIs and a PI/r * No evidence of any primary HIV genotypic mutations in HIV reverse transcriptase or protease for all patients with available resistance testing results conducted prior to cART and/or during viral rebound/failure * Provision of written, informed consent. Exclusion Criteria: * CXCR4 or CCR5/CXCR4 dual tropic HIV tropism or a non-reportable tropism result based on assessment using proviral DNA * Anticipated need to modify current cART regimen for toxicity management in the next 6 months * The following laboratory criteria, 1. absolute neutrophil count (ANC) \<750 cells/µL 2. haemoglobin \<8.0 g/dL 3. platelet count \<50,000 cells/µL 4. serum AST, ALT \>5 x upper limit of normal (ULN) * Active hepatitis B co-infection * Pregnant women or nursing mothers * Current use of any prohibited medications as described in product specific information. * Hypersensitivity to soy or peanuts * Acute therapy for serious infection or other serious medical illness (in the judgement of the site Principal Investigator) requiring systemic treatment and/or hospitalisation * Use of immunomodulators (e.g. systemic corticosteroids, recombinant interleukin-2, interferon) within 30 days prior to screening * Patients with current alcohol or illicit substance use that in the opinion of the site Principal Investigator would conflict with any aspect of the conduct of the study * Patients unlikely to be able to remain in follow-up for the protocol-defined period * Prisoners or subjects who are compulsorily detained (involuntary incarcerated).